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OBJECTIVE: To evaluate the concordance between the Gleason scores of prostate biopsies and radical
prostatectomy specimens, thereby highlighting the importance of the prostate-specific antigen (PSA) level as a
predictive factor of concordance.
METHODS: We retrospectively analyzed 253 radical prostatectomy cases performed between 2006 and 2011.
The patients were divided into 4 groups for the data analysis and dichotomized according to the preoperative
PSA, ,10 ng/mL and $10 ng/mL. A p-score ,0.05 was considered significant.
RESULTS: The average patient age was 63.3¡7.8 years. The median PSA level was 9.3¡4.9 ng/mL. The overall
concordance between the Gleason scores was 52%. Patients presented preoperative PSA levels ,10 ng/mL in
153 of 235 cases (65%) and $10 ng/mL in 82 of 235 cases (35%). The Gleason scores were identical in 86 of 153
cases (56%) in the ,10 ng/mL group and 36 of 82 (44%) cases in the $10 ng/mL group (p=0.017). The biopsy
underestimated the Gleason score in 45 (30%) patients in the ,10 ng/mL group and 38 (46%) patients in the
$10 ng/mL (p=0.243). Specifically, the patients with Gleason 3 + 3 scores according to the biopsies
demonstrated global concordance in 56 of 110 cases (51%). In this group, the patients with preoperative
PSA levels ,10 ng/dL had higher concordance than those with preoperative PSA levels $10 ng/dL (61% x 23%,
p=0.023), which resulted in 77% upgrading after surgery in those patients with PSA levels $10 ng/dl.
CONCLUSION: The Gleason scores of needle prostate biopsies and those of the surgical specimens were
concordant in approximately half of the global sample. The preoperative PSA level was a strong predictor of
discrepancy and might improve the identification of those patients who tended to be upgraded after surgery,
particularly in patients with Gleason scores of 3 + 3 in the prostate biopsy and preoperative PSA levels $10 ng/
mL.
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& INTRODUCTION
Despite the variability in incidence, prostate cancer (PC)
remains one of the most prevalent cancers worldwide, and
in many countries, it is the leading cause of cancer death
among men. In 2012, the estimate of PC deaths in the
European Union was 69,960, corresponding to 10.74 deaths
per 100,000 men (1). In the United States, the 2012 estimate
was 241,740 new PC cases and 28,170 deaths (2). In 2012 in
Brazil, there was an estimated 60,180 new PC cases,
representing an estimated risk of 62 new cases per 100,000
men (3).
In 1966, based on the histological architecture of the
tumor, Donald F. Gleason developed a grading system for
PC (4). Many changes have occurred since then (5). The
currently accepted classification for the Gleason score (GS)
was conceived in 2005, the consensus known as "The 2005
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Consensus Conference on Gleason Grading of Prostatic
Carcinoma," aimed to standardize the score. The result of
this consensus was the exclusion of Gleason’s pattern 1 in
diagnosing prostate carcinoma, the near extinction of
pattern 2 and some modifications in the diagnostic standard
of patterns 3, 4 and 5 (6).
The Gleason score and prostate-specific antigen (PSA)
level are the most important prognostic factors in
prostate cancer. Several studies have reported great dis-
crepancy between needle biopsies and radical prostatect-
omy (RP) specimens. The concordance of the Gleason
score depends on certain clinical factors, such as the PSA
dosage, number of cores at prostate needle biopsy and
experience level of the pathologist. The biopsy Gleason
score is a key factor in deciding the appropriate treatment,
including selecting patients for RP, external beam radio-
therapy (with or without neo and adjuvant androgen
suppressive therapy), brachytherapy, expectant manage-
ment and active surveillance. However, the definitive
Gleason score can only be obtained after RP. The RP-based
Gleason score appears to be a stronger predictor of PSA-
based failure after RP than the biopsy-based Gleason score
(7). The discrepancy between the biopsy and RP Gleason
scores might result in inappropriate treatment recommen-
dations.
Using population-based data from the pathology reports
collected from a southern Brazilian hospital, the purpose of
the present study was to examine the concordance between
the reported biopsy-based and RP-based Gleason scores and
to identify the pretreatment factors, mainly the PSA levels,
that could predict an upgrade from a Gleason score of 6 in
the biopsy to $7 in the RP specimen.
& PATIENTS AND METHODS
The patients treated with radical retropubic prostatect-
omy between 2006 and 2011 were reviewed. Data from 253
patients were analyzed. All prostate biopsies had at least 12
needle cores.
The following exclusion criteria were applied: previous
transurethral resection of the prostate (TURP) or open
prostatectomy, using 5 alpha-reductase inhibitors (finaster-
ide and dutasteride), adjuvant hormonal treatment, pro-
longed urethral catheterization, urinary tract infection,
symptomatic chronic prostatitis and urinary bladder calculi.
Patients with a biopsy Gleason score containing pattern 1 or
2 were also excluded. Based on these criteria, 18 patients
were excluded from further analysis: 4 reported with
Gleason pattern 2, 7 had previous TURP, 4 had urinary
retention using prolonged urethral catheterization, 1 had a
urinary tract infection, one was using finasteride and 1 had
a preoperative treatment with goserelin.
We compared the Gleason score in the last preoperative
cancer-positive needle biopsy with the Gleason score
obtained from the surgical specimen. The patients were
divided into 4 groups based on the biopsy Gleason score: 3 +
3, 3 +4, 4 + 3 and $8. To obtain an accurate prostate weight,
the RP specimen description was used.
As some prostate biopsies were evaluated by different
pathologists from outside institutions, additional analyses
were included to identify any differences in the concordance
rates between the biopsies analyzed by outside general
pathologists and the staff uropathologist. The effect of PSA
on the data analysis was evaluated considering a cutoff
value of 10 ng/mL.
In all the analyses, a p-score ,0.05 was considered
significant. All statistical tests (analysis of variance
[ANOVA], Mann-Whitney U-test, Kruskal-Wallis) were
performed with SPSS 16.0 software.
This study was approved by the local Research Ethics
Committee and acknowledged by the National Commission
of Research Ethics (CONEP) and Institutional Review Board
(IRB).
& RESULTS
The average patient age was 63.3¡7.8 years (range 35 to 77
years). The preoperative PSA level in this studied population
ranged from 0.8 to 47.2 ng/mL, with a median of 9.3¡4.9 ng/
mL. The mean prostate weight of the RP specimens was
48.9¡19.8 g (19-121 g). The median number of positive core
biopsies was 4.0¡2.8 (1-14), and 45% of the global sample
were bilateral. These data are expressed in Table 1.
The presence of Gleason scores 3 + 3, 3 + 4, 4 + 3 and $8
occurred in 47%, 31%, 17% and 5%, respectively, in the
needle biopsies and in 28%, 42%, 23% and 7%, respectively,
in the final histopathological analysis of the surgical
specimens. The most frequent Gleason scores were 3 + 3
(47%) in the needle biopsy and 3 + 4 (42%) in the RP
specimens (p= 0.011). These data are shown in Figure 1.
The preoperative PSA levels were higher in the groups 4 +
3 and$8 (p,0.05). There was no significant difference in the
mean PSA level between groups 3 + 3 and 3 + 4 (p.0.05).
The median number of biopsy cores was 14.2¡3.9,
without a significant difference among the 4 groups. The
number of previous prostate biopsies among groups 3 + 3, 3
+ 4 and 4 + 3 was similar (p.0.05), and all patients in group
$8 were diagnosed in the first prostate biopsy.
The number of cores positive for malignancy grew with
the progression of the Gleason score but did not reach a
significant value among the 4 groups (p.0.05). The same
effect was observed in the percentage of patients diagnosed
with bilateral tumors in the prostate biopsy. The prostate
weight was higher in groups 3+3 and $8 (p,0.05).
The comparison of the Gleason scores from the biopsy
and RP specimens demonstrated identical scores in 122
cases (52%), under-grading in 83 cases (35%) and over-
grading in 30 cases (13%) (Table 1). Evaluating 168 of the 235
(71%) cases that had either a needle biopsy or RP specimen
analyzed inside our institution, we observed results similar
to the global sample: 55% concordance, 32% under-grading
and 13% over-grading of the Gleason score in the prostate
biopsy (p.0.05).
Overall, 153 (65%) and 82 (35%) patients presented
preoperative PSA levels of ,10 and $10 ng/mL, respec-
tively. The Gleason scores from the biopsy and RP speci-
mens were identical in 86 of 153 patients (56%) and 36 of 82
patients (44%), respectively (p= 0.017). The biopsy Gleason
score was underestimated in 45 of 153 (30%) patients with
PSA levels ,10 ng/mL and 38 of 82 patients (46%) with
PSA levels $10 ng/dL (p= 0.243). Overestimation of the
Gleason score was similar in patients with PSA levels
,10 ng/mL and $10 ng/dL, (14% vs. 10%, respectively,
p= 0.708) (Table 2).
Considering patients with PSA levels ,10 ng/dL, the
concordance in the Gleason score was 61%, 61%, 33% and
0% for patients in the 3 + 3, 3 + 4, 4 + 3 and $8 groups,
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respectively. Patients with preoperative PSA levels $10 ng/
dL had concordance in 23%, 50%, 68% and 44% of cases in
the 3 + 3, 3 + 4, 4 + 3 and $8 groups, respectively.
Specifically, patients with Gleason score 3 + 3 in the
prostate biopsy demonstrated global concordance in 56 of
110 cases (51%). In this group, patients with a preoperative
PSA level ,10 ng/mL had higher identical Gleason scores
(61%, p = 0.023). With a preoperative PSA level $10 ng/mL,
this group showed a concordance rate of 23%, resulting in
77% of patients with an upgraded Gleason score after
radical prostatectomy (Figure 2).
& DISCUSSION
According to the literature, the Gleason score discrepancy
between the needle prostate biopsy and RP ranged between
35% and 76%. Some of the most important studies (Table 3)
have described predictive factors for Gleason concordance
(8-21).
The rates of discrepancy are influenced by the number of
biopsy cores. This aspect could be observed in the elegant
study conducted by San Francisco et al., which observed an
exact concordance of 76% for 12 core biopsies and 63% for 6
core biopsies (13). Additionally, Mian et al. (15) described
concordance rates of 68% and 48% for a mean of 12.4 and
6.7 cores, respectively. Today, the discussion about the
number of cores in s prostate biopsy is obsolete because
sextant biopsy is no longer considered adequate (22). The
British Prostate Testing for Cancer and Treatment Study
has recommended a minimum of 10 core biopsies (23).
Taking more than 12 cores is not significantly more
conclusive (24).
Some articles have also described that the reproducibility
of the Gleason score depends on the pathologist’s experi-
ence and education level (19). However, in our series, there
was not a significant difference in Gleason score concor-
dance between the prostate biopsy analyses performed
inside and outside our institution. The consensus conference
in 2005, which was organized by the International Society of
Urological Pathology (ISUP) (6), modified the Gleason
grading system, eliminating pattern 1 and almost extin-
guishing pattern 2; this change might reduce the difference
between high and low volume pathology units (19). In
addition, ignoring,5% of Gleason pattern 3 at biopsy in the
presence of pattern 4 or 5 was recommended. The updated
grading system may be one reason why the most recent
studies have shown a higher concordance in the Gleason
scores, as shown in Table 3.
Most studies (14-21) performed after the resolution of the
ISUP Consensus, including the current study, have demon-
strated a rate of concordance ranging from 50% to 76%; in
contrast, in studies published before 2005, the concordance
rate ranged from 35% to 76% (8-13). Interestingly, San
Francisco et al. (2003) demonstrated a higher concordance in
their series, which may be attributed to the fact that a
different extended biopsy approach was adopted, whereas
most prior studies have included biopsies with fewer than
10 cores.
Figure 1 - Frequency of the Gleason score distribution in the
prostate biopsy (PB) and radical prostatectomy (RP) specimens in
the study population. * The most frequent Gleason scores were 3
+ 3 in prostate biopsy and 3 + 4 in the RP specimens (p=0.011).
Table 1 - Patient demographics, laboratory results and a comparison of the Gleason scores of prostate biopsy (PB) and
radical prostatectomy (RP) specimens in the study population.
Gleason score
3+3 3+4 4+3 $4+4 TOTAL p-value
N. of patients 110 73 40 12 235 -
Age (X ¡ S), years 63.7¡7.1 62.4¡6.5 63.8¡6.8 64.1¡7.8 63.3¡7.8 0.3861
Race
Caucasian (%) 84 (76%) 58 (79%) 30 (75%) 9 (75%) 181 (77%) 1.0002
African-Brazilian (%) 26 (24%) 15 (21%) 10 (25%) 3 (25%) 54 (23%) 1.0002
PSA (X ¡ SD), ng/mL 8.6¡4.3 9.3¡5.2 15.9¡9.4 14.5¡6.3 9.3¡4.9 0.0011 *
Previous biopsies (X ¡ SD), n 0.4¡0.8 0.3¡0.8 0.2¡0.5 0 0.3¡0.8 0.2962
Prostate weight (X ¡ SD), g 51.9¡21.3 45.6¡18.5 46.5¡15.8 51.9¡16.4 48.9¡19.8 ,0.0011**
Number of biopsy cores (X ¡ SD), n 15.1¡4.8 13.8¡3.7 14.9¡3.6 13.5¡3.9 14.2¡3.9 0.5732
Positive cores (X ¡ SD), n 3.1¡1.9 4.6¡3.1 5.2¡2.1 9.3¡3.6 4.0¡2.8 0.7862
Biopsy positive bilaterally
Yes (%) 42 (38%) 31 (42%) 24 (60%) 9 (75%) 106 (45%) 1.0002
No (%) 68 (62%) 42 (58%) 16 (40%) 3 (25%) 129 (55%) 1.0002
Gleason score
PB=RP (%) 56 (51%) 42 (58%) 20 (50%) 4 (33%) 122 (52%) 0.1842
PB,RP (%) 54 (49%) 22 (30%) 5 (12%) 2 (17%) 83 (35%) 0.2642
PB.RP (%) - 9 (12%) 15 (38%) 6 (50%) 30 (13%) 0.0712
Legend: 1- ANOVA test; 2 - Mann-Whitney U-test. p,0.05 as significant. PSA: prostate-specific antigen.
*Preoperative PSA levels were higher in the 4+3 and $4+4 groups. ** Prostate weight was higher in the 3+3 and $8 groups.
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The importance of the preoperative PSA levels and their
correlation with the Gleason score has also been described.
Kvale et al. (19) described 39%, 50% and 57% Gleason
upgrading rates in radical prostatectomy with PSA levels of
,10, 10 to 14.9 and $15 ng/mL, respectively; interestingly,
the upgrading of the Gleason score was associated with
increasing PSA levels. In the current study, considering PSA
values, and $ than 10 ng/mL, a similar relationship could
be observed (Table 2). The most concerning issue is that
approximately 80% of the patients with Gleason scores of 3
+ 3 and PSA levels of $10 ng/mL were upgraded after their
RP surgical specimens were analyzed. This observation
indicates that PSA levels $10 ng/mL with Gleason scores
,7 should be carefully evaluated.
There are some implications associated with this conclu-
sion. As a PSA level $10 ng/dL excludes patients from
being diagnosed as low-risk, according to D’Amico (25), the
prostate cancer risk classification also excludes these
patients from being offered transperineal brachytherapy or
active surveillance. Indeed, if radiation therapy is the chose
curative modality treatment, hormonal therapy should be
added (26).
Table 2 - PSA levels, patient demographics and comparison of the Gleason scores of prostate biopsy (PB) and radical
prostatectomy (RP) specimens.
PSA values (ng/mL)
,10 $10 p-value
N. of patients 153 82 -
Age (X ¡ SD), years 63.1¡7.1 64.3¡6.5 0.3041
Race
Caucasian (%) 121 (79%) 60 (73%) 1.0002
African-Brazilian (%) 32 (21%) 22 (27%) 1.0002
PSA (X ¡ SD), ng/dL 6.5¡2.1 15.3¡6.1 ,0.0011
Previous biopsies (X ¡ SD), n 0.3¡0.7 0.3¡0.8 0.7812
Prostate weight (X ¡ SD), g 47.0¡18.8 53.0¡20.8 0.7081
Number of biopsy cores (X ¡ SD), n 14.3¡3.7 13.9¡4.7 0.7212
Positive cores (X ¡ SD), n 3.4¡2.2 5.3¡3.3 0.1782
Biopsy positive bilaterally
Yes (%) 54 (35%) 52 (63%) 0.5162
No (%) 99 (65%) 30 (27%) 0.8972
Gleason Score
PB=RP (%) 86 (56%) 36 (44%) 0.0172
PB,RP (%) 45 (30%) 38 (46%) 0.2432
PB.RP (%) 22 (14%) 8 (10%) 0.7082
Legend: 1- ANOVA test; 2 - Kruskal-Wallis test. p,0.05 as significant.
Figure 2 - Concordance of Gleason score (GS) 3 + 3 in the needle
prostate biopsy (PB) and radical prostatectomy (RP) according to
preoperative prostate-specific antigen (PSA) levels , and
$10 ng/dL. * The patients with preoperative PSA levels
,10 ng/dL had higher concordance rates (61% vs. 23%) than
the patients with preoperative PSA$10 ng/dL (p,0.023). p,0.05
was significant.
Table 3 - Results of the current study and published series regarding the concordance between the Gleason score (GS) of
prostate biopsy (PB) and radical prostatectomy (RP) specimens.
N. of patients GS PB = RP GB PB , RP GS . RP
Steinberg et al. (1997) (8) 499 58% 36% 6%
Djavan et al. (1998) (9) 415 37% 50% 13%
D’Amico et al. (1999) (10) 653 35% 51% 14%
King CR (2000) (11) 428 41% 42% 17%
Noguchi et al. (2001) (12) 222 36% 46% 18%
San Francisco et al. (2003) (13) 126 76% 14% 10%
Chun et al. (2006) (14) 4,789 54% 33% 13%
Mian et al. (2006) (15) 225 68% 17% 15%
Divrik et al. (2007) (16) 392 56% 37% 10%
Kato et al. (2008) (17) 153 50% 37% 13%
Fine et al. (2008) (18) 1,455 76% 18% 6%
Kvale et al. (2009) (19) 1,116 53% 38% 9%
Moreira Leite et al. (2009) (20) 464 57% 29% 14%
Tapia et al. (2011) (21) 168 63% 27% 10%
Current study 235 52% 35% 13%
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These data highlight the necessity of obtaining a reliable
Gleason score, which is not always possible with a prostate
biopsy. We emphasize that regardless of the available
treatment options after a prostate cancer diagnosis, the
Gleason score directly influences the treatment modality to
be used (e.g., the extent of pelvic lymphadenectomy in RP,
the dose of radiotherapy and its association or not with
androgen deprivation therapy, the possibility of perform-
ing brachytherapy or even active surveillance).
Establishing the final Gleason score by prostate biopsy
alone is highly questionable and might involve making
decisions based on data that are not always correct.
Additionally, this study discusses the importance of PSA
levels in the actual prostate cancer itself and in determining
the best treatment option.
In conclusion, the Gleason scores of the needle prostate
biopsies and those of the radical prostatectomy specimens
were concordant in approximately half of the global sample.
Moreover, the real impact of our results was in highlighting
the importance of the preoperative PSA level in the
concordance of the Gleason score. Together with clinical
factors, the preoperative PSA level may improve the
identification of those patients who tend to be upgraded
after surgery, mainly the patients with the 3 + 3 Gleason score
in the prostate biopsy with a preoperative PSA $10 ng/mL.
Despite efforts of the ISUP to standardize Gleason score
analyses, the discrepancy between biopsy and RP persists.
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